|Bid||15.90 x 0|
|Ask||16.30 x 0|
|Day's Range||15.91 - 16.08|
|52 Week Range||12.88 - 18.14|
|Beta (3Y Monthly)||-0.04|
|PE Ratio (TTM)||31.81|
|Earnings Date||Nov 11, 2019|
|Forward Dividend & Yield||0.20 (1.25%)|
|1y Target Est||10.83|
-Once daily Aczone® 7.5% Gel is proven to treat acne vulgaris in 12 week clinical studies. -Expanded indication extends approved use of Aczone® 7.5% Gel to patients 9-11 years of age, building on 2016 ...
EXTON, Pa., July 25, 2019 /PRNewswire/ -- Almirall, S.A. (ALM) announced today the opening of a new call for proposals for their AlmirallShare open innovation platform, looking to find partners to identify, validate or test new targets for the treatment of chronic immune-inflammatory diseases of the skin, such as psoriasis, atopic dermatitis and pemphigus vulgaris. By merging science and creativity of experts around the world and Almirall's own expertise, this initiative aims to accelerate the generation of new treatments for skin diseases.
climbed 3.4% to $9.29 Thursday after Mizuho upgraded shares of the biopharmaceutical company to buy from neutral. Analyst Irina Koffler also lowered her price target for the Menlo Park, California-based company to $14 from $17 a share.
- Almirall honored with the Distinguished Corporate Leadership Award - Recognized for their contribution to the field of dermatology and efforts to overcome skin diseases - Award accepted by Ron Menezes, ...
- Results show that 44% and 54% of patients in studies KX01-AK-003 and KX01-AK-004, respectively, achieved 100% AK lesion clearance at Day 57. - Safety profile of KX2-391 ointment may be an important competitive ...
- Almirall has entered into a definitive agreement with Celling Biosciences for an undisclosed amount. - Celling Biosciences is a biotech company focused on the science, research and development of autologous cellular therapy. EXTON, Pa., March 4, 2019 /PRNewswire/ -- Almirall S.A. (ALM) announced that it has entered into a definitive agreement with Celling Biosciences, based in Austin (Texas), to divest ThermiGen for an undisclosed amount.
Results show that 44% and 54% of patients in studies KX01-AK-003 and KX01-AK-004, respectively, achieved 100% AK lesion clearance at Day 57 Safety profile of KX2-391 ointment.
EXTON, Pa., Feb. 5, 2019 /PRNewswire/ -- Almirall, S.A. (ALM), today announced that an abstract reporting the results from two Phase III studies of KX2-391 Ointment in the treatment of actinic keratosis has been accepted for presentation at the Late-Breaking Research Program at the 2019 American Academy of Dermatology Annual Meeting, to take place March 1–5, 2019 in Washington, DC. The presentation (Abstract 11216), with the title "KX2-391 Ointment 1%, a Novel Dual Src/Tubulin Inhibitor, is Efficacious and Safe in the Treatment of Adults with Actinic Keratosis in Two Phase III Studies", will be delivered in Session S034 (Late-breaking Research: Clinical Trials) on Saturday, March 2, 2019, between 1:00pm and 4:00pm Eastern Time in Ballroom A at the Walter E. Washington Convention Center.
EXTON, Pa., Jan. 17, 2019 /PRNewswire/ -- Almirall LLC announces the launch of Seysara™ (sarecycline), a novel tetracycline-derived oral antibiotic developed specifically for the treatment of acne. Seysara™ was approved in October 2018 by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe non-nodular inflammatory acne vulgaris in patients 9 years of age and older, and is now commercially available. "Seysara™ was the first new chemical entity for the treatment of acne to be approved by the FDA in a decade, and the acquisition of the product in September 2018 represented a significant investment by our company in the future of medical dermatology," said Peter Guenter, CEO of Almirall.
Rating Action: Moody's affirms Almirall's Ba3 CFR; stable outlook. Global Credit Research- 18 Dec 2018. Paris, December 18, 2018-- Moody's Investors Service has today affirmed the Ba3 corporate family ...
EXTON, Pa., Oct. 19, 2018 /PRNewswire/ -- Almirall, LLC, formerly Aqua Pharmaceuticals, a U.S. leader in skin health medical solutions, used the start of the Fall Clinical Dermatology Congress to officially launch their new name. Almirall, LLC is part of the larger Almirall, S.A. family, an internationally-recognized global dermatology pharmaceutical company, with a strong focus on skin health.